

CellaVision announces preliminary first quarter results 2023

First quarter preliminary results 2023

- Net sales decreased by 14% to SEK 139 m (162)
- EBITDA margin amounted to 25% (36)

“Coming off two soft quarters in a row, temporary inventory reductions at distribution partners due to the uncertain economic climate had an adverse effect on the first quarter 2023. Post-COVID-implications in the important market of China has further slowed growth. These challenges have resulted in a deviation from our growth ambition.

However, distribution partners indicate that the underlying growing demand for digital cell morphology remains and that inventory levels have now normalized. We therefore expect our order pattern to improve throughout 2023.

Increased cost control has been implemented but investments in research and development will be continued to support our long-term financial ambition.”

Simon Østergaard, President & CEO

Contact

Adele Horn
Corporate Communications & Investor Relations
Direct: + 46 46 460 26 04
Mobile: + 46 72 206 50 88
www.cellavision.com
adele.horn@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 16 local market support organizations covering more than 40 countries. In 2022, sales were SEK 639 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-17 19:45 CEST.

Attachments

[CellaVision announces preliminary first quarter results 2023](#)
[CellaVision Announces Preliminary First Quarter Results 2023](#)